Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380179 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL18410414 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL13380178 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL12564941 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL13380172 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL15117423 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL18410378 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL18410411 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL20883293 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL21083135 | 0.90 | OPRD1 (0.54) | OPRM1OPRD1OPRK1CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202396-B2 | Process for improved opioid synthesis | RHODES TECHNOLOGIES (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202396-B2 | Process for improved opioid synthesis | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.